Health and Healthcare
Merck (MRK): The Beatings Will Continue Until Morale Improves
Published:
Big Pharma continues to throw ballast out of the balloon in the hopes of staying aloft. The latest victim of declining fortunes in the industry is Merck (MRK), which seems to have had every drug which it submitted to the FDA this year turned down.
Merck’s cholesterol medicine Cordaptive got the thumbs down last week. Researchers are also questioning the value of its Vytorin product, another cholesterol treatment which does not seem to work.
According to The Wall Street Journal, Merck will cut 1,200 sales jobs.
There are more to come. The problems Merck has replacing drugs which are coming off-patent are getting deeper and deeper.
Douglas A. McIntyre
Buffett Missed These Two…
Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.
But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.
Unlock the two dividend legends Buffett missed in this new free report.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
